{"name": "Medivation",
 "permalink": "medivation",
 "crunchbase_url": "http://www.crunchbase.com/company/medivation",
 "homepage_url": "http://www.medivation.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@medivation.com",
 "phone_number": "(415) 543-3470",
 "description": "",
 "created_at": "Mon May 28 02:50:12 UTC 2012",
 "updated_at": "Fri Feb 08 23:11:29 UTC 2013",
 "overview": "\u003Cp\u003EMedivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc. (Astellas), the Company is developing MDV3100 for multiple stages of advanced prostate cancer. As of December 31, 2011, it completed a Phase III trial in the latest stage. The Company\u0026#8217;s three subsidiaries include Medivation Prostate Therapeutics, Inc. (MPT), Medivation Neurology, Inc. (MNI) and Medivation Technologies, Inc. (MTI). MPT holds the Company\u2019s MDV300 series technology, which is in development for the treatment of advanced prostate cancer, and MTI holds its earlier stage technologies. MNI holds its dimebon technology, which was in development for the treatment of Alzheimer\u2019s disease and Huntington disease. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       34],
      "assets/images/resized/0019/2030/192030v1-max-150x150.png"],
     [[235,
       54],
      "assets/images/resized/0019/2030/192030v1-max-250x250.png"],
     [[235,
       54],
      "assets/images/resized/0019/2030/192030v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "David",
      "last_name": "Hung",
      "permalink": "david-hung-2",
      "image": null}},
   {"is_past": false,
    "title": "Chief Business Officer, CFO",
    "person":
     {"first_name": "C.",
      "last_name": "Patrick Machado",
      "permalink": "c-patrick-machado",
      "image": null}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "Kathryn",
      "last_name": "E. Falberg",
      "permalink": "kathryn-e-falberg",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "201 Spear Street",
    "address2": "3rd Floor",
    "zip_code": "94105",
    "city": "San Francisco",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:MDVN"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}